Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

New and emerging treatments for osteoporosis.

Clarke BL.

Clin Endocrinol (Oxf). 2009 Sep;71(3):309-21. doi: 10.1111/j.1365-2265.2009.03541.x. Review.

PMID:
19222491
2.

Emerging therapies in osteoporosis.

MacDonald BR, Gowen M.

Best Pract Res Clin Rheumatol. 2001 Jul;15(3):483-96. Review.

PMID:
11485342
3.

Future therapeutic targets in osteoporosis.

Deal C.

Curr Opin Rheumatol. 2009 Jul;21(4):380-5. doi: 10.1097/BOR.0b013e32832cbc2a. Review.

PMID:
19461517
4.

Emerging and potential therapies for osteoporosis.

Grey A, Reid IR.

Expert Opin Investig Drugs. 2005 Mar;14(3):265-78. Review.

PMID:
15833058
5.

[Anabolic therapy of osteoporosis].

Okopień B, Krysiak R, Labuzek K, Herman ZS.

Pol Merkur Lekarski. 2005 Jul;19(109):118-21. Review. Polish.

PMID:
16194044
6.

Potential new drug targets for osteoporosis.

Deal C.

Nat Clin Pract Rheumatol. 2009 Jan;5(1):20-7. doi: 10.1038/ncprheum0977. Review. Erratum in: Nat Clin Pract Rheumatol. 2009 Mar;5(3):174.

PMID:
19098925
7.

Current and emerging therapies for osteoporosis.

Mitchner NA, Harris ST.

J Fam Pract. 2009 Jul;58(7 Suppl Osteoporosis):S45-9. Review.

PMID:
19825319
8.

[Effect of anabolic steroids on osteoporosis].

Adachi M, Takayanagi R.

Clin Calcium. 2008 Oct;18(10):1451-9. doi: CliCa081014511459. Review. Japanese.

PMID:
18830042
9.

Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Martin TJ, Sims NA, Ng KW.

Osteoporos Int. 2008 Aug;19(8):1125-38. doi: 10.1007/s00198-008-0575-5. Review.

PMID:
18338097
10.

Anabolic agents and the bone morphogenetic protein pathway.

Garrett IR.

Curr Top Dev Biol. 2007;78:127-71. Review.

PMID:
17338916
11.

Pharmacogenomics of osteoporosis: opportunities and challenges.

Nguyen TV, Eisman JA.

J Musculoskelet Neuronal Interact. 2006 Jan-Mar;6(1):62-72. Review.

12.

Emerging drugs for postmenopausal osteoporosis.

Lewiecki EM.

Expert Opin Emerg Drugs. 2009 Mar;14(1):129-44. doi: 10.1517/14728210902766813 . Review.

PMID:
19249985
13.

Clinical findings on the therapeutic action of a long-acting anabolic agent.

Luppino V.

Panminerva Med. 1965 Oct;7(10):392-8. No abstract available.

PMID:
5320934
14.

Novel targets and therapeutics for bone loss.

Margolis RN, Wimalawansa SJ.

Ann N Y Acad Sci. 2006 Apr;1068:402-9. Review.

PMID:
16831939
15.

Treatment options for osteoporosis and decision making criteria: 2009.

Ortiz-Luna G, García-Hernández P, Tamayo-Orozco JA.

Salud Publica Mex. 2009;51 Suppl 1:S114-25.

16.

A review of anabolic therapies for osteoporosis.

Lane NE, Kelman A.

Arthritis Res Ther. 2003;5(5):214-22. Review.

17.

Pharmacogenetics of osteoporosis: future perspectives.

Marini F, Brandi ML.

Calcif Tissue Int. 2009 May;84(5):337-47. doi: 10.1007/s00223-009-9226-x. Review.

PMID:
19271099
18.

[Treatment of osteoporosis with an enolic ether of dihydrotestosterone. (Clinical studies)].

Domeniconi S.

Chir Organi Mov. 1966;54(5):409-14. Italian. No abstract available.

PMID:
5333788
19.

[Biological monitoring during treatments of systemic osteoporosis. Therapeutic deductions].

Eisinger J, Laponche AM, Moulard JC, Serratrice G, Recordier AM.

Rev Rhum Mal Osteoartic. 1971 Apr;38(4):265-8. French. No abstract available.

PMID:
5563138
20.

[On the osteoporosis therapy with anabolic steroids].

Krüskemper HL.

Med Welt. 1965 Jun 12;24:1347. German. No abstract available.

PMID:
5828648
Items per page

Supplemental Content

Support Center